Companion Animal Cardiac Drugs Market Size, Share & Trends Analysis Report By Product (Pimobendan, Spironolactone and Benazepril, Furosemide, Others), By Animal Type (Dogs, Cats, Horses, Others), By Distribution Channel (Hospital and Clinic Pharmacies, Retail Pharmacies, E Commerce) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Companion Animal Cardiac Drugs Market Size & Share Analysis

The global companion animal cardiac drugsmarket size was valued at USD 2.24 billion in 2025 and is projected to grow from USD 2.423 billion in 2026 to USD 4.71 billion by 2034, registering a CAGR of 8.60% during the forecast period (2026-2034). North America dominated the companion animal cardiac drugs  market with a share of 42.1% in 2025.

Companion animal cardiac drugs are veterinary pharmaceutical products designed to manage cardiovascular conditions in pets, primarily dogs and cats. They are generally classified under HSN Code 3004 (medicaments for therapeutic or prophylactic uses), while SIC Code 2834 covers pharmaceutical preparations.

The companion animal cardiac drug market demand is driven by the prevalence of cardiovascular disorders in pets, the expansion of advanced veterinary healthcare services, and a focus on long-term cardiac disease management. Veterinary healthcare providers are adopting cardiac medications such as pimobendan, diuretics, and ACE inhibitors, contributing to companion animal cardiac drug market growth.

Companion Animal Cardiac Drugs Market Segmentation Analysis

By Product

Pimobendan accounted for a share of 42.5% in 2025, owing to its established use in managing congestive heart failure in dogs and improving cardiac function. Widespread adoption of pimobendan-based treatments by veterinary practitioners supports demand for cardiac medications, strengthening the segment's position in the companion animal cardiac drug market.

The spironolactone and benazepril segment is anticipated to record a growth rate of 8.8% during the forecast period, driven by the demand for effective heart failure management, wider use of combination drug therapies in veterinary practice, and the need for long-term treatment of cardiovascular conditions in companion animals.

Request Customizationto receive a tailored report.

By Animal Type

Dogs dominated the animal type segment with a share of 68.5% in 2025 due to the widespread use of cardiac medications to manage canine cardiovascular conditions, including congestive heart failure and dilated cardiomyopathy. 

Cats are projected to undergo growth at a CAGR of 9.8% during the forecast period, fueled by increasing awareness of feline heart conditions, including hypertrophic cardiomyopathy, and the rising demand for specialized veterinary cardiac treatments. The emphasis on early diagnosis and long-term management of feline cardiovascular diseases also support the adoption of cardiac medications for cats.

By Distribution Channel

In 2025, hospitals and clinic pharmacies led the distribution channel segment with a share of 57.8%. This dominance is led by the direct availability of prescribed cardiac medications and the need for veterinarian-guided treatment of cardiovascular conditions in companion animals.

Retail pharmacies are likely to witness a CAGR of 8.3% during the forecast period, supported by the availability of veterinary cardiac medications and convenient access to prescribed treatments. The demand for long-term medication management among pet owners is expected to support retail pharmacy sales of companion animal cardiac drugs.

Speak to an Analystto discuss market opportunities.

Companion Animal Cardiac Drug Market Regional Analysis

North America Companion Animal Cardiac Drug Market

The North America companion animal cardiac drug market accounted for a dominant share of 42.1% in 2025.

U.S. Companion Animal Cardiac Drug Market

U.S. Food and Drug Administration (FDA) requires veterinary drugs, including companion animal cardiac medications, to meet applicable standards for safety, efficacy, and quality before approval and marketing. These requirements encourage manufacturers to develop improved cardiac formulations and advance treatments for canine and feline heart conditions, including heart failure, arrhythmias, and other cardiovascular diseases.

Canada Companion Animal Cardiac Drug Market

According to Agriculture and Agri-Food Canada, Canada had 17.3 million dogs and cats in 2025, reflecting a substantial population of companion animals requiring veterinary healthcare. Thus, the need for diagnosis and long-term management of canine and feline heart conditions supports demand for companion animal cardiac drugs in Canada.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Companion Animal Cardiac Drugs Market

The Asia Pacific companion animal cardiac drugs market will expand at a CAGR of 7.68%, showcasing the fastest-growing regional market.

Japan Companion Animal Cardiac Drugs Market

Japan’s Ministry of Agriculture, Forestry and Fisheries (MAFF) supports veterinary vaccine development and regulatory oversight through its animal health policies and initiatives. These efforts encourage vaccine innovation, improved formulations, and the development of products targeting canine and feline infectious diseases, supporting the adoption of advanced companion animal vaccines in Japan.

China Companion Animal Cardiac Drugs Market

The Chinese market is supported by rising pet ownership, increasing expenditure on veterinary healthcare, and growing awareness of preventive vaccination among pet owners. Investments in veterinary healthcare infrastructure and the expansion of animal health services improve access to routine immunization. These developments continue to strengthen demand for dog vaccines, cat vaccines, and other veterinary pharmaceuticals in China.

India Companion Animal Cardiac Drugs Market

The Department of Animal Husbandry and Dairying introduced Pashu Aushadhi, a programme for distributing affordable generic veterinary medicines through selected Pradhan Mantri Kisan Samriddhi Kendras and cooperative societies. The government identified 134 generic veterinary medicines and related consumables for procurement. This initiative provides a distribution model that can improve access to veterinary medicines, while demand for treatments such as pimobendan for canine congestive heart failure supports the need for specialised companion-animal cardiac drugs.

Europe Companion Animal Cardiac Drugs Market

Europe's companion animal cardiac drugs market is anticipated to grow at a CAGR of 8.1% during the forecast period.

UK Companion Animal Cardiac Drugs Market

Research by the Royal Veterinary College has demonstrated the benefits of pimobendan in delaying the onset of congestive heart failure in dogs with preclinical degenerative mitral valve disease. These findings support evidence-based treatment practices and demand for cardiac medications for long-term cardiovascular disease management.

Germany Companion Animal Cardiac Drugs Market

European Medicines Agency authorises veterinary cardiac medicines such as Cardalis, containing benazepril and spironolactone, and Vetmedin, containing pimobendan, for relevant canine cardiac conditions. This established treatment landscape supports demand for cardiac drugs that help manage heart failure and improve long-term disease control in companion animals. The EU Veterinary Medicines Information database lists generic benazepril tablets authorised in Germany, alongside combination therapies such as Cardalis, which contains benazepril and spironolactone.

Latin America Companion Animal Cardiac Drugs Market

The Latin America companion animal cardiac drugs market is projected to grow at a CAGR of 9.2% during the forecast period. Brazil’s Ministry of Agriculture and Livestock opened a public consultation on regulations for registering generic and interchangeable veterinary medicines, while a bill introduced in September 2026 proposed incentives for their production and sale. 

Mexico’s National Service for Agrifood Health, Safety and Quality (SENASICA) updated its veterinary product regulation information, including registration and authorisation processes for animal-use pharmaceuticals. Across both markets, the expansion of veterinary diagnostic services and greater attention to long-term management of companion animal heart conditions support market development.

Middle East & Africa Companion Animal Cardiac Drugs Market

The Middle East & Africa companion animal cardiac drugs market is anticipated to grow at a CAGR of 8.9% during the forecast period. UAE’s Federal Decree-Law No. 21 of 2025, effective January 2026, governs the registration, approval, manufacturing, marketing and distribution of veterinary medical products. This framework supports the supply of authorised cardiac medicines for dogs and cats, including treatments for congestive heart failure and other cardiovascular conditions.

South African Health Products Regulatory Authority (SAHPRA) issued an advisory reinforcing compliance with national requirements for veterinary medicines, including the risks associated with unregistered products. This regulatory focus supports demand for registered cardiac medicines used to manage canine congestive heart failure.

Competitive Landscape

The companion animal cardiac drug market competitive landscape is competitive, with established veterinary pharmaceutical companies and animal health product developers. Key players such as Boehringer Ingelheim, Ceva Santé Animale, Elanco Animal Health, Dechra Pharmaceuticals, and Vetoquinol are estimated to account for 35-45% of the global companion animal cardiac drug market share.

Established players compete mainly through treatment effectiveness, product safety, veterinary approval and distribution networks. Regional players in companion animal cardiac drug ecosystem focus on specialized cardiac treatments, affordable veterinary medicines, and therapies for heart conditions in dogs and cats.

List of Key and Emerging Players in Companion Animal Cardiac Drugs Market